Praxair (PX) Reports Q1 EPS of $1.37

Praxair (NYSE: PX) reported Q1 EPS of $1.37, versus $1.24 reported last year. Revenue for the quarter came in at $2.73 billion, versus $2.51 billion reported last year.

• Strong financial performance
  • Sales of $2.7 billion, 9% above prior-year quarter
  • Operating cash flow of $0.7 billion, 28% above prior-year quarter
  • EPS of $1.35, up 9% vs. prior-year quarter; adjusted EPS of $1.37, up 7%
• Successful execution of our core strategy
  • Volume growth of 4% vs. prior-year quarter, driven by North America, Europe and Asia
  • Resilient end-markets rise to 28% of sales
  • Backlog $1.5 billion; includes recently announced Celanese project win in U.S. Gulf Coast
• Continued progress toward definitive merger agreement with Linde AG

For earnings history and earnings-related data on Praxair (PX) click here.

You May Also Be Interested In

• Goldman Sachs to acquire Neos for up to $2.25b cash and stock
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance